Binary risk in investing is the situation where a stock’s value hangs on a single pending event that can only resolve one of two ways, and the price will jump or collapse to a new level the moment the answer arrives. There is no gentle slide in between. A biotech waiting on an FDA verdict, a company defending its core patent, a takeover target waiting for antitrust clearance — the stock sits near a consensus price until the news hits, then relocates. Managing that kind of exposure is a different job from managing ordinary market risk, and the usual tools quietly fail at it.
What Binary Risk Actually Does to a Position
In normal trading, prices drift on a stream of information: earnings, upgrades, economic data. Binary risk strips that away. The asset’s value is effectively frozen around a consensus expectation until the decisive piece of information drops, at which point the price leaps to a completely new level without trading at any price in between. Traders call this gapping, and it is the defining mechanical feature of binary events.
Gapping is what makes binary risk different from garden-variety volatility. In a normal decline you can sell at progressively lower prices and limit the damage. When a stock gaps from $80 to $30 at the open because a trial failed, there was never a moment where you could have sold at $60 or $50. You don’t get the chance to react.
Historical volatility also stops meaning what it usually means. A company waiting on a single regulatory verdict may have traded in a tight range for months, producing low volatility readings that make the stock look calm. The calm is part of the pattern, not evidence against the storm.
Where Binary Risk Shows Up
FDA Drug Decisions
Pharmaceutical and biotech stocks are the textbook case. Under the Prescription Drug User Fee Act, the FDA commits to acting on a standard new molecular entity within 10 months of accepting the filing, or within 6 months for drugs granted priority review.1U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures The target date, known as the PDUFA date, becomes the single most important day on the company’s calendar.
For a small biotech with one drug in its pipeline, that date is all-or-nothing. Approval means revenue, partnerships, and a stock that might double or triple. A rejection, or even a request for more data, can cut the stock in half overnight, because the company may have spent years and hundreds of millions of dollars getting to that point with nothing else to fall back on.
Patent Verdicts
A court ruling on patent infringement can be just as decisive. When a competitor challenges a key patent, the revenue stream tied to that product hangs on the outcome. A favorable ruling preserves the monopoly. An unfavorable one opens the door to generics or copycats and can wipe out most of the stock’s value in a session. Patent verdicts often arrive with less warning than FDA dates, which makes the timing harder to plan around even when the stakes are obvious.
Mergers and Acquisitions
Deals create a different flavor of binary risk. Once an acquisition is announced, the target’s stock typically trades just below the agreed buyout price, with the discount reflecting the chance the deal falls apart. If the deal clears, the stock snaps to the buyout price. If regulators block it, the stock drops to wherever it would have traded without the premium, often 20% to 40% lower. Merger arbitrageurs live in this space, collecting the discount and wearing the downside when the regulatory math changes.
Signs That a Binary Event Is Approaching
The options market is the most reliable early warning. As a known binary event draws closer, implied volatility climbs because traders will pay more for options that could pay off on a big move. If a stock might jump 40% or fall 50% next week, the right to buy or sell at today’s price is genuinely valuable, and you can watch the premium inflation build in the weeks before a PDUFA date or a major verdict.
The moment the event resolves, that premium evaporates. Implied volatility can drop 30% to 40% or more in a single session, a phenomenon known as volatility crush. This happens regardless of direction. Even if the stock gaps up on good news, options priced for uncertainty lose most of their time value because the uncertainty is gone. Traders who bought options purely to bet on the event often lose on both sides: the stock moved, but not enough to overcome the collapse in the premium they paid.
The bid-ask spread on the underlying stock tells a parallel story. In the hours before resolution, the gap between buyers and sellers tends to widen sharply while volume drops. Market makers know the next trade could be at a radically different price, so they widen their quotes to compensate. That liquidity drought is itself a warning that the market has priced in a violent move.
Why Standard Risk Tools Mislead You Here
Most financial risk models assume price changes follow something close to a bell curve: small moves often, extreme moves rare. Binary risk violates that assumption. The actual distribution looks more like a Bernoulli: two possible values and nothing in between. The mathematical average of a 60% chance of gaining $20 and a 40% chance of losing $30 is +$0, but the stock will never trade there. It will be at +$20 or -$30. The average outcome is a fiction no investor will experience.
Value at Risk, the industry standard for measuring downside, struggles with the same problem. VaR tells you the worst loss you should expect on, say, 95% of trading days, based on recent price history. Binary events don’t care about historical percentiles. When the price gaps past every intermediate level, the actual loss can far exceed what VaR predicted. The right framing is the probability of the specific event occurring and the size of the gap if it goes wrong, not backward-looking volatility.
Stop-loss orders have the same weakness. A stop set below the current price looks like insurance, but if the stock gaps below your stop at the open, the order converts to a market order and fills at whatever price is available. A stop-limit refuses to sell below your limit, but then the order may never fill at all if the stock blows past that level without a single trade in between. In a true binary gap, neither order type protects you the way it would in normal trading.
Sizing and Hedging the Position
The most common options play around a binary event is the long straddle: buy a call and a put at the same strike and expiration. If the stock moves far enough in either direction, one side pays off more than the combined premium. The catch is that the market knows the event is coming, so the premiums are already inflated to reflect the expected move. You profit only if the actual move exceeds what the options market priced in, which is a higher bar than it sounds.
Position sizing is where experienced binary traders actually control their risk. The Kelly Criterion offers a framework: the optimal fraction of capital to allocate is the probability of winning minus the probability of losing divided by the payout ratio. In practice, most professionals use a fraction of the Kelly amount, because the formula assumes you know the true probabilities, which you rarely do with precision in a binary setup. The working rule is simpler. Size the position so the worst-case loss won’t materially damage your portfolio. If you can’t afford to lose the whole thing, it’s too large for a binary bet.
Tax Treatment If the Bet Goes Wrong
When a binary event destroys a stock’s value, what you can do about it on your taxes depends on how bad the damage is and what you do next. If you sell at a loss, the IRS lets you deduct capital losses against capital gains dollar for dollar. If your losses exceed your gains for the year, you can deduct up to $3,000 of the excess against ordinary income ($1,500 if married filing separately). Anything beyond that carries forward to future tax years.2Internal Revenue Service. Topic No. 409, Capital Gains and Losses
For a stock that lost 80% on a failed FDA decision, $3,000 a year is a slow way to recover a five- or six-figure loss. The math gets worse if you also had capital gains elsewhere that year, because those gains absorb part of the loss before the $3,000 against ordinary income even comes into play. Tax-loss harvesting — selling the loser to lock in the deduction and redeploying the cash — is the usual move. Watch the wash sale rule, though: if you buy back the same stock or a substantially identical security within 30 days before or after the sale, the IRS disallows the loss entirely.3Office of the Law Revision Counsel. 26 USC 1091 – Loss From Wash Sales of Stock or Securities
If the stock doesn’t just decline but becomes truly worthless, a separate provision applies. Under IRC § 165(g), a security that becomes completely worthless during the tax year is treated as if it were sold on the last day of that year for zero.4Office of the Law Revision Counsel. 26 USC 165 – Losses It’s still a capital loss, subject to the same $3,000 annual limit against ordinary income, but the December 31 “sale” date matters for determining whether the loss is short-term or long-term. You don’t need to actually sell the shares. You do need to show the security has no remaining value, not just that it fell sharply. A stock trading at $0.10 is not worthless for tax purposes; a stock delisted after the company dissolved likely is.
What Happens After the Gap
The initial gap on a binary event is dramatic, but it isn’t always the end. Academic research has documented a pattern called post-announcement drift, where the stock continues moving in the direction of the surprise for weeks or even months. The effect has been studied most extensively around earnings announcements, with measurable drift persisting for up to a year in some cases. Markets don’t fully absorb the implications of new information in one session, even when the information arrives all at once.
For FDA approvals, the drift often reflects the market gradually pricing in the commercial details that follow the yes-or-no answer: launch timelines, insurance coverage, competitive dynamics, manufacturing ramp. The approval is binary; the revenue implications unfold over months. After a rejection, the drift can continue downward as analysts revise their models, institutional holders unwind, and the company’s options for salvaging the product become clearer. The initial gap sets the new baseline. Where the stock finally settles can be meaningfully different from where it opened on event day, and that gives you some room to adjust, provided you still have a position left to adjust.